The IMA Group Announces Acquisition of Pontum Health
Adds Pacific Northwest to IMA’s growing Evaluation Services network.

TARRYTOWN, N.Y.–(BUSINESS WIRE)–Further extending its service area to two key new states and strengthening it in an existing market, The IMA Group (IMA) announced today the acquisition of Pontum Health, a regional provider of Social Security Disability evaluations currently operating in the Pacific Northwest.

The IMA Group Acquires Accelemed Research Institute
Transaction expands IMA’s footprint to more than 20 sites; growing its Southwest presence.

TARRYTOWN, N.Y.–(BUSINESS WIRE)–With its announcement of the acquisition of Accelemed Research Institute in Austin, TX, The IMA Group (IMA) continues to grow its presence in the Southwest and its capabilities in a broad range of clinical trials. The acquisition of Accelemed expands the company’s depth in multi-therapeutic clinical trial sites focused on cardiometabolic and GI diseases such as non-alcoholic steatohepatitis (NASH), obesity, high cholesterol, and diabetes. Terms of the transaction were not disclosed.

The IMA Group Announces Leadership Appointment in Clinical Research Division
Industry Veteran Dana Poff Joins Rapidly Expanding Team

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA), a leading technology-enabled provider of clinical trials and medical and psychological screening and evaluation services, announced today that industry veteran Dana Poff would lead IMA’s Clinical Research Division as Executive Vice President. IMA Clinical Research is a flexible, full-service clinical trial network consisting of geographically diverse clinical trial sites and over 150 satellite sites that conduct site-based, hybrid and decentralized clinical trials.

The IMA Group acquires Clinical Trials of America
IMA Clinical Research Has Grown 300% Over Past Three Years; Transaction Increases Division’s Network to 17 Sites and Expands Access to Patients in Additional Therapeutic Areas

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) today announced it had completed the acquisition of Clinical Trials of America (CTA), a multi-therapeutic clinical trials company that brings to IMA four new independent and six embedded site locations in Louisiana and North Carolina.

The IMA Group acquires Mollie Kallen Case Management to Expand National Footprint
Marks 4th acquisition in 2022; strengthens depth in Florida, Illinois, Michigan and Ohio

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group announced today its acquisition of Mollie Kallen Case Management (MKCM), marking the company’s fourth acquisition this year. With the addition of MKCM to its portfolio, IMA further expands its national case management services in its rapidly growing Payer Services division. In addition to Orchard Medical Consulting, acquired in May of 2021, MKCM allows IMA to expand its offerings nationally, including the key states of Florida, Georgia, Illinois, Michigan and Ohio.

988 Suicide and Crisis LifeLine Call or Text

July 12, 2022 – Suicide is the 12th leading cause of death in the U.S. In 2020 alone, the U.S. had one death by suicide every 11 minutes, and suicide attempts for the same time period are estimated at 1.2 million.

On July 16th the nationwide 988 Suicide and Crisis Lifeline, will be made live. Anyone experiencing mental health related distress, whether that is thoughts of suicide, mental health or substance use crisis or any other kind of emotional distress will be able to call or text for help. People can also dial 988 if they are worried about a loved one who many need crisis support.  It will be operational 24/7, be free, and confidential. Trained crisis counselors will be available to quickly respond in multiple languages through the call feature. Text will only be available for the time being in English.

If you, or someone you know, is experiencing a mental health crisis, call or text 988 for assistance starting July 16, 2022. Prior to July 16, assistance is still available through the national Lifeline 1-800-273-8255.

Sources:

Suicide Statistics | ASFP

988 Suicide and Crisis Lifeline | SAMHSA

The Intersection of 911 and 988: Decriminalizing Mental Health Crises – The Health Care Blog

The IMA Group names Work Comp and Managed Care Industry Executive Rob Snow Senior Vice President, Sales and Marketing

TARRYTOWN, N.Y.–(BUSINESS WIRE)–Rob Snow, a workers’ compensation and managed care industry veteran with more than 20 years of experience, has joined The IMA Group (IMA) as Senior Vice President for Sales and Marketing. IMA is one of the nation’s leading providers of medical and psychological evaluations, working with employers, insurance carriers, TPAs, and government agencies nationwide. The company also provides one of the industry’s top networks of clinical research sites.

UMC Medical Consultants, An IMA Group Company, is Available on NY Workers’ Compensation Board’s OnBoard Medical Portal

TARRYTOWN, N.Y. –Effective Monday, May 2nd, the prior authorization request (PAR) types for Treatment/Testing was implemented in OnBoard, New York State’s Workers’ Compensation Board’s claims system.  UMC is an approved Medical Review Organization (MRO) capable of processing prior authorization requests.

Payers in New York can now submit claims to UMC for treatment and testing through the OnBoard web-based system when they designate UMC as their preferred MRO. The web-based claims system replaces the legacy paper-based system and offers improved expanded access to real-time claim data, self-serve features and improved responsiveness.

The IMA Group Continues National Growth with Acquisition of Amici Clinical Research
Newest acquisition adds two clinical trial sites to IMA’s clinical research network

TARRYTOWN, N.Y. – March 2, 2022 – The IMA Group (IMA) announced today the acquisition of Amici Clinical Research, a clinical trials company with two New Jersey sites in Raritan and Hoboken.  Expanding IMA’s metro New York presence, Amici brings therapeutic expertise in fatty liver, cardiovascular, pulmonary, and neurologic diseases to IMA Clinical Research.  The company also has extensive experience conducting endocrinology, dermatology, and vaccine studies, among the fastest-growing categories of clinical research today.

The IMA Group Announces Acquisition of Redlink, Inc., a Social Security Disability Evaluation Company
Move adds seven new states to IMA’s growing network and builds out presence in West

TARRYTOWN, N.Y.–(BUSINESS WIRE)–Extending its service area to seven new states and strengthening it in seven existing markets,The IMA Group (IMA) announced today the acquisition of Redlink, Inc., a regional provider of Social Security Disability evaluations currently operating in the Western United States. The acquisition continues IMA’s long-standing commitment to providing quality Social Security Disability Consultative Examinations (CEs) and positions it to further expand its portfolio of service offerings in rapidly growing markets.

The IMA Group Announces Acquisition of Exemplar Research, Inc.
Move broadens IMA’s access to diverse patient populations in underserved areas.

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) announced today the acquisition of Exemplar Research, Inc. (ERI), a community-based specialty research clinic with an outpatient facility serving the North Central region of West Virginia. The move marks IMA’s fourth acquisition in as many months and further broadens its access to diverse populations in underserved areas.

The IMA Group Announces Acquisition of Diagnostics Research Group
Newest acquisition strengthens and broadens IMA’s clinical research offerings

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) announced today the acquisition of Diagnostics Research Group (DXRG), a clinical research site in San Antonio, Texas, with expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies, and pulmonary and fatty liver diseases.

The IMA Group Continues Growth with Acquisition of Albuquerque Neuroscience, Inc.
Acquisition Deepens IMA’s Clinical Trials Expertise and Reach

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) announced today the acquisition of Albuquerque Neuroscience, Inc., a clinical research site specializing in diseases of the central nervous system (CNS) and general medical conditions.

The IMA Group announces acquisition of MedPlus Disability Evaluations.
Newest acquisition adds 7 states to IMA’s network and expands national footprint and service area

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group (IMA) announced today the acquisition of MedPlus Disability Evaluations, a regional provider of Social Security Disability evaluations throughout the Southeast and Southwest United States. The acquisition furthers IMA’s long-standing commitment to providing quality Social Security Disability Consultative Examinations (CE’s) and positions it to further expand the company’s portfolio of service offerings in rapidly growing markets.

Further Expanding Its Capabilities and Footprint, The IMA Group Acquires Orchard Medical Consulting
Latest acquisition adds nurse case and disability management

TARRYTOWN, N.Y.–(BUSINESS WIRE)–The IMA Group announced today its acquisition of Orchard Medical Consulting, marking the company’s fourth such venture in 24 months. The latest expansion adds case and disability management capabilities to the company’s comprehensive clinical programs and services, strengthening its service offering and geographic coverage.

Mike Minor and Deb Nichols Join The IMA Group as Executives in Clinical Research
Industry veterans bring more than 65 years of combined clinical, operational, commercial, strategic and scientific experience.

NEW YORK, May 19, 2021 — The IMA Group announced today the ongoing expansion of its Clinical Research Division through the addition of two industry veterans with over 65 years of combined clinical, operational, commercial, strategic and scientific experience.

IMA Clinical Research is a physician-founded network of 10 integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With access to 80 additional, broadly distributed medical offices of The IMA Group, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and decentralized clinical trials that support the development of safe and effective therapies. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical trial participants for pharmaceutical sponsors.

AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement
IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observe health management in a non-trial setting, advancing future trial recruitment criteria.

NEW YORK, March 15, 2021 — AiCure, an AI and data analytics company focused on improving clinical trials, and IMA, a national leader in providing clinical evaluation and research services, today announced a partnership to gain a widespread understanding of patient behavior and drug compliance outside of a clinical trial setting. With a database of over 300,000 potential subjects, IMA will roll out AiCure’s patient engagement solution, Patient Connect, to study participants, offering patients convenient and enhanced support to successfully manage their existing treatment at home.

The IMA Group Acquires EVOnational, an IME Services Provider
Latest acquisition adds 7,000 providers to IMA’s network and further expands its scope

Tarrytown, NY – February 23, 2021– The IMA Group (IMA) announced today it has acquired EVOnational, a national provider of independent medical exams (IMEs), medical screenings and other evaluations. The acquisition extends IMA’s scope and capabilities while enhancing its national offering of behavioral and medical evaluations. The company serves the workers’ compensation, liability, disability and auto markets.   

Financial terms of the acquisition for the two privately held companies were not disclosed. To ensure a seamless transition for existing clients, EVOnational will continue to operate under its current name, with key leadership, processes and staff remaining in place.

“EVOnational brings our company the services, programs and people to ideally enhance and complement what we already offer our clients,” said IMA’s President Mark Weinberger, Ph.D., MPH. “Their experience and commitment to their clients, emphasis on technology designed for our industry and excellent provider panel give us the ability to help clients tackle the tough challenges facing the industry today.”

Beyond Diversity: IMA Clinical Research Taps into Underserved Patient Populations

The FDA has issued guidance that promotes the inclusion of diverse populations in clinical trials to better understand the risk and benefits across all groups. The traits of these groups can include gender, race, ethnicity, age and location of residency. With today’s focus on the topic, Dr. Howard Chipman, Principal Investigator, IMA Clinical Research, shares his insights, focusing on the importance of geographic footprints, as well as factors some may not consider, such as non-demographic traits.

Dr. Mario Rocci Joins The IMA Group as Strategic Advisor in Clinical Research
Industry veteran to expand company’s Clinical Research Division

Tarrytown, NY – January 12, 2021 – Mario Rocci, PhD, FCP, FFIP, a seasoned executive with 35 years of scientific and business management experience, has joined The IMA Group (IMA) as Strategic Advisor in the Clinical Research division.

IMA Clinical Research is a network of integrated research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA performs trials with a flexible model using both their physical locations and virtual capabilities that reach people around the country to support the advancement of safe and effective medication therapies.  Additionally, IMA also maintains a robust study participant database to recruit and complete trials efficiently. 

“Given the current international attention on clinical trials stemming from the COVID-19 pandemic, there is an increasing emphasis for quality, reputable research that can be delivered quickly,” said Mark Weinberger, PhD, MPH, President of IMA. “Mario shares our excitement for the growth of IMA through its unique network of sites and infrastructure.  His extensive background in pharma, both in academia and industry, will greatly enhance IMA’s leadership team with greater visibility and standing in the field.”

The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19.

The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19. The individual saliva swab diagnostic test, developed by SUNY Upstate Medical University and Quadrant Biosciences, recently received emergency approval by the FDA. The new test, will be used with Upstate Medical’s and Quadrant’s innovative pool testing, which allows for 10 to 25 people to be screened in one COVID-19 test.

The IMA Group partners with Rensselaer County on COVID-19 testing for students

We are very proud to partner with Rensselaer County to provide two dedicated days of COVID-19 testing for college students. 

Clinical Research Studies During the COVID-19 Pandemic Public Health Emergency

Jennifer Goldfarb, MSN, RN, CCRP, VP of IMA’s Clinical Research,  recently wrote an article for the Society of Clinical Research Associates (SOCRA) entitled Defining a “New Normal” in Clinical Research to Support the World’s 336,747 Research Studies

In Response To COVID-19 Pandemic PsyBar Expands Its HIPAA-Compliant, IME, Pre-Employment & Fitness For Duty Teleassessment Exam Services

MINNEAPOLIS, MN – May 5, 2020 — PsyBar, a division of The IMA Group and one of the nation’s leading specialty providers of disability, workers’ compensation and other employment-related behavioral health forensic evaluations, has responded to the country’s need to address mental health issues related to the nation’s shutdown as a result of the COVID-19 pandemic by expanding its teleassessment services.

Urgently-needed behavioral health forensic pre-employment, independent medical exams (IMEs) and fitness for duty exam (FFDE) evaluations can now be provided via a secure, online platform.

Rensselaer County announces COVID-19 testing sites

RENSSELAER COUNTY, N.Y. — The county is partnering with Whitney Young and IMA Group with LabCorp to have testing sites next week.

According to Rensselaer County Executive Steve McLaughlin, Whitney Young will set up mobile testing sites in the city of Troy and the city of Rensselaer beginning next week.

The testing with IMA Group and Lab Corp is expected to start next week and will be conducted at Hudson Valley Community College.

The IMA Group Announces Acquisition of PsyBar, Expands Footprint as Single Source Provider

Company now offers network of national, board-certified psychologists, neuropsychologists and psychiatrists for range of IME, pre-employment, Fitness for Duty and disability screenings, as well as other services

Tarrytown, NY – February 26, 2020 – Recognizing the growing importance of quality behavioral health programs for payers, The IMA Group (IMA) announced today the acquisition of PsyBar, one of the nation’s leading specialty providers of behavioral health, independent medical exams (IME), and other employment related services.

Financial terms of the acquisition were not disclosed. To ensure a seamless transition for existing clients, PsyBar will continue to operate under its current name, with all key leadership remaining in place.